Allergan assuages shareholder fears over losing Restasis patent

Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis.The drugmaker, which also announced third-quarter earnings, said it will combat generic competition for the drug by expanding its base business, reducing costs and possibly buying back stock."But rest assured, we will do it rapidly."Allergan worked hard in recent years to protect Restasis,which